Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, double-blind, placebo-controlled study

CNS Drugs

Volumn 19, Issue 2, 2005, Pages 125-136

  Dodick, David ^a   Brandes, Jan ^b   Elkind, Arthur ^c   Mathew, Ninan ^d   Rodichok, Lawrence ^e  

^a MAYO CLINIC   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Elkind Headache Center   (United States)

^d Houston Headache Clinic   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZOLMITRIPTAN;

ABSCESS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; MIGRAINE AURA; MULTICENTER STUDY; NAUSEA; NOSE IRRITATION; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SOMNOLENCE; SORE THROAT; SUICIDAL BEHAVIOR; THORAX PAIN; THROAT DISEASE;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; DRUG TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLIDINONES; PAIN MEASUREMENT; REACTION TIME; RECURRENCE; SEROTONIN AGONISTS; SUMATRIPTAN; TIME FACTORS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 14644391549     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200519020-00003     Document Type: Article

References (22)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001; 41: 546-57
2. Terwindt GM, Ferrari MD, Tijhuis M, et al. The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000; 55: 624-9
3. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology 2000; 55 Suppl. 2: 529-35
4. MacGregor EA, Brandes J, Eikermann A, et al. Impact of migraine on patients and their families. The Migraine and Zolmitriptan Evaluation (MAZE) survey: phase III. Current Med Res Opin 2004; 20: 1143-50
5. Von Korff M, Stewart WF, Simon DJ, et al. Migraine and reduced work performance: a population-based diary study. Neurology 1998; 50: 1741-5
6. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2: 67-76
7. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159: 813-8
8. Uemura N, Charlesworth B, Onishi T, et al. Zolmitriptan is detectable in plasma 2 to 5 minutes after administration by nasal spray [abstract]. Headache 2003; 43: S159
9. Kågedal M, Duvauchelle T, Hovsepian L, et al. Zolmitriptan demonstrates good pharamcokinetic consistency between and within individuals following intranasal administration. Br J Clin Pharmacol 2004; 57: 679-80
10. Yates R, Nairn K, Dixon R, et al. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J Clin Pharm 2002; 42: 1237-43
11. Bergström M, Wall A, Kågedal M, et al. An open label positron emission tomography study to investigate the distribution of intranasally administered [11C] zolmitriptan into the CNS. Neurology 2004; 62 (7 Suppl. 5): A80-1
12. Zingmark P-H, Yates R, Hedlund C, et al. True nasopharyngeal absorption of zolmitriptan following administration of zolmitriptan nasal spray [abstract]. Eur J Neurol 2003; 10 Suppl. 1: 76
13. Charlesworth BR, Dowson AJ, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003; 17 (9): 653-67
14. Gawel M, Aschoff J, May A, et al. Zolmitriptan 5mg nasal spray: efficacy and onset of action in the acute treatment of migraine. Results from the REALIZE study. Headache 2005; 45: 7-16
15. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
16. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-6
17. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22
18. Dowson AJ, Charlesworth BR, Purdy A, et al. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs 2003; 17 (11): 839-51
19. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39 Suppl. 2: S20-6
20. Lipton RB, Hamelsky SW, Danyo JM. What do patients want from acute migraine treatment? Headache 2002; 42 Suppl. 1: 3-9
21. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation study. Headache 2003; 43: 19-26
22. MacGregor EA. The doctor and the migraine patient; improving compliance. Neurology 1997 (Suppl 3): S16-20